Ackrell Capital, LLC
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
FINRA / SIPC
|
Membership |
7
|
3 | |
|
organization
FINRA
|
Membership |
6
|
2 | |
|
organization
SIPC
|
Membership |
6
|
2 | |
|
organization
Wana Brands
|
Investment analysis |
5
|
1 | |
|
person
FINRA/SIPC
|
Membership |
5
|
1 | |
|
organization
VCC Brands
|
Investment analysis |
5
|
1 | |
|
organization
Uber
|
Investment analysis |
5
|
1 | |
|
organization
Vapexhale
|
Investment analysis |
5
|
1 | |
|
organization
SC Labs
|
Business associate |
1
|
1 |
HOUSE_OVERSIGHT_024694.jpg
This document is page 58 of a Cannabis Investment Report created by Ackrell Capital, LLC in December 2017. It analyzes the 'Business Solutions Outlook' and 'Digital Media' segments of the cannabis industry, discussing market opportunities for software, big data, and media platforms that do not directly handle the plant. The document bears a 'HOUSE_OVERSIGHT_024694' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely related to financial probes involving banks or individuals connected to the investigation.
HOUSE_OVERSIGHT_024693.jpg
This document is page 57 of a 2017 industry report by Ackrell Capital, LLC regarding Cannabis Industry Segmentation. The text analyzes 'Business Services' and 'Business Solutions,' outlining opportunities in industry-specific software, integrated platforms, and big data analytics, as well as challenges regarding deployment risks and low barriers to entry. The document bears a House Oversight Bates stamp, indicating it was part of a congressional investigation document production.
HOUSE_OVERSIGHT_024692.jpg
This document is page 56 of a December 2017 Cannabis Investment Report produced by Ackrell Capital, LLC. It analyzes risks regarding FDA approval and product liability, outlines the outlook for consumer products (flower, edibles, etc.), and discusses business solutions and software within the cannabis industry. The document bears a 'HOUSE_OVERSIGHT_024692' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024689.jpg
This document is a page from an Ackrell Capital report discussing the segmentation of the cannabis industry, specifically focusing on accessories. It highlights the growing market for storage and transportation products driven by safety regulations and changing social taboos, featuring images of consumers using vaporizers and examples of products like 'Stink Sack' bags and storage cases.
HOUSE_OVERSIGHT_024686.jpg
This document is page 50 of a 'Cannabis Investment Report' published by Ackrell Capital, LLC in December 2017. It functions as a visual catalog of various cannabis edible products, including chocolates, sparkling water, mints, and gummies from brands like Défoncé, Mountjoy, Breez, and Valhalla. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024686', indicating it was part of a discovery production for the House Oversight Committee, though the page content itself is strictly related to cannabis market research.
HOUSE_OVERSIGHT_024685.jpg
This page from an Ackrell Capital report details the 'Infused Products' segment of the cannabis industry, breaking down sales by category for Q3 2017 in Colorado, Oregon, and Washington. It specifically highlights 'Edibles,' explaining their manufacturing, consumption methods, metabolic processes, and distinct physiological effects compared to inhalation.
HOUSE_OVERSIGHT_024683.jpg
This document is page 47 of a 2017 report by Ackrell Capital, LLC regarding 'Cannabis Industry Segmentation.' It provides a technical overview of cannabis concentrates, specifically comparing solvent-based (hydrocarbon, CO2, ethanol) and solvent-free extraction methods. It includes market data from Q3 2017 for Colorado, Oregon, and Washington provided by BDS Analytics. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production, the text contains no references to Jeffrey Epstein, associates, or specific financial transactions.
HOUSE_OVERSIGHT_024682.jpg
This document is page 46 of a 'Cannabis Investment Report' dated December 2017, published by Ackrell Capital, LLC. The text provides an industry overview of 'Cannabis Flower' and 'Concentrates,' discussing product types, strains (e.g., Blue Dream, OG Kush), and THC content. It appears to be part of a larger document dump collected by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024682), likely included in evidence files, though the specific page contains no direct references to Epstein or his associates.
HOUSE_OVERSIGHT_024680.jpg
This document is page 44 of a Cannabis Investment Report published by Ackrell Capital in December 2017. It analyzes the 'Distribution Outlook' for the cannabis industry, discussing tax issues, regulatory challenges in states like Colorado, California, and Nevada, and compares US distribution models to international markets like Germany and Uruguay. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely produced as evidence for a congressional committee.
HOUSE_OVERSIGHT_024679.jpg
This document is page 43 of a 2017 investment report titled 'Chapter III Cannabis Industry Segmentation' produced by Ackrell Capital, LLC. It analyzes 'Distribution Services' within the cannabis market, outlining opportunities such as e-commerce and branded dispensaries, as well as challenges like customer acquisition and restrictive regulations. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024679', indicating it was part of a production to the House Oversight Committee.
HOUSE_OVERSIGHT_024677.jpg
This document appears to be page 41 of an Ackrell Capital industry report from 2017 regarding the cannabis industry. It specifically focuses on 'Chapter III: Cannabis Industry Segmentation' and contains six photographs illustrating dispensary operations, including exterior views (featuring the 'Apothecarium'), interior views (featuring 'Elemental'), and customer interactions. The document bears a House Oversight Bates stamp.
HOUSE_OVERSIGHT_024675.jpg
This document is page 39 of a 2017 investment report by Ackrell Capital, LLC regarding the Cannabis Industry (specifically Chapter III: Segmentation). It outlines opportunities and challenges in cannabis production, discussing topics such as specialized production services, energy efficiency, testing certification, scaling operations, and access to capital. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, though the text itself contains no specific references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024674.jpg
This document is page 38 of a December 2017 Cannabis Investment Report by Ackrell Capital, LLC. It displays a sample 'Certificate of Analysis' from SC Labs detailing potency, terpene, pesticide, and residual solvent test results for a cannabis product. The specific client and sample details are redacted/pixelated, and the document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024674), indicating it was part of a larger document production likely related to a congressional investigation.
HOUSE_OVERSIGHT_024671.jpg
This document is page 35 of a 2017 industry report by Ackrell Capital regarding the cannabis industry. It details the economics and logistics of cannabis cultivation, comparing indoor vs. outdoor/greenhouse methods, and discusses legal challenges regarding interstate commerce. The document bears a 'HOUSE_OVERSIGHT_024671' stamp, indicating it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024669.jpg
This document is page 33 of a 2017 report by Ackrell Capital, LLC, providing an overview of the cannabis cultivation process. It functions as an informational graphic detailing the timeline and stages of growing cannabis, from seed selection to curing. While bearing a House Oversight Bates stamp often associated with investigations, the content of this specific page is purely technical industry analysis regarding cannabis agriculture.
HOUSE_OVERSIGHT_024666.jpg
This document is page 30 of a 'Cannabis Investment Report' dated December 2017, produced by Ackrell Capital, LLC. It contains a table titled 'Representative Dosage Amounts' detailing THC and CBD dosages for various ailments (e.g., Anxiety, Cancer, Glaucoma) and a paragraph discussing the lack of thorough research on the medical benefits and side effects of cannabis. The document bears the stamp 'HOUSE_OVERSIGHT_024666', indicating it is part of a document production to the House Oversight Committee, likely related to a financial investigation.
HOUSE_OVERSIGHT_024665.jpg
This document is page 29 of a 2017 investment report by Ackrell Capital regarding 'Cannabis Science 101.' The text discusses synthetic cannabinoids (mentioning Marinol/dronabinol), the 'entourage effect,' and general safety and dosage guidelines for cannabis use. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024665,' indicating it was produced as evidence in a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024664.jpg
This document is page 28 of a Cannabis Investment Report dated December 2017 by Ackrell Capital. It details the science of cannabis genetics, propagation, and cloning methods (clipping vs. tissue culture), mentioning specific researchers Jon Page and Timothy Hughes who mapped the genome of the 'Purple Kush' variety in 2011. The document bears a 'HOUSE_OVERSIGHT_024664' Bates stamp, suggesting it was part of a document production for a congressional investigation, likely related to financial records or investment portfolios reviewed during the Epstein probes.
HOUSE_OVERSIGHT_024663.jpg
This document is page 27 of a 2017 report by Ackrell Capital titled 'Cannabis Science 101'. It details the THC/CBD formulation spectrum and lists medical conditions treated by different ratios (e.g., Alzheimer's, Cancer, Anxiety). The text explains the 'entourage effect,' the role of terpenes like Myrcene, and the concept of 'Frankensteining' in cannabis formulations. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024663', indicating it was part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024661.jpg
This document is page 25 of a report titled 'Cannabis Science 101' produced by Ackrell Capital, LLC in 2017. The text provides scientific descriptions of various terpenes found in cannabis (Caryophyllene, Humulene, Limonene, Linalool, Myrcene, Pinene, and Terpinolene), detailing their aromas, sources in nature, and potential medicinal benefits. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was included in evidence for a House Oversight Committee investigation, likely regarding financial dealings or industry research connected to the subjects of the investigation.
HOUSE_OVERSIGHT_024656.jpg
This document is page 20 of a Cannabis Investment Report dated December 2017, produced by Ackrell Capital, LLC. It details scientific information regarding cannabinoids, specifically contrasting THC and CBD, and provides a matrix of medical conditions (such as Cancer, ALS, and Glaucoma) alongside the specific cannabinoids used to treat them. The document bears a 'HOUSE_OVERSIGHT_024656' Bates stamp, indicating it was part of a document production for the House Oversight Committee, though the text itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024655.jpg
This document is page 19 of a 2017 report by Ackrell Capital titled 'Cannabis Science 101'. It discusses the biological mechanisms of Human Endocannabinoids (specifically anandamide/AEA) and the Endocannabinoid Systems in nonhuman mammals. It includes a diagram of the canine endocannabinoid system. The document bears a 'HOUSE_OVERSIGHT_024655' stamp, indicating it was part of a document production to the House Oversight Committee, though the content itself is strictly scientific and industry-related.
HOUSE_OVERSIGHT_024654.jpg
This document is page 18 of a 'Cannabis Investment Report' published by Ackrell Capital, LLC in December 2017. It provides a scientific overview of the Human Endocannabinoid System, specifically detailing the functions and locations of CB1 and CB2 receptors in the body. It bears the Bates stamp 'HOUSE_OVERSIGHT_024654', indicating it was part of a document production for a congressional investigation, though the specific page contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024652.jpg
This document is page 16 of a Cannabis Investment Report produced by Ackrell Capital in December 2017. It provides a biological overview of cannabis, detailing the differences between Sativa, Indica, and Ruderalis leaves, and explaining chemical compounds such as cannabinoids (THC, CBD) and terpenes. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained as part of a congressional investigation, likely related to inquiries into Jeffrey Epstein's finances or investments, though no specific individuals are named on this page.
HOUSE_OVERSIGHT_024651.jpg
This document is page 15 of a 2017 report by Ackrell Capital titled 'Cannabis Science 101'. It provides a botanical overview of the cannabis plant, describing the three principal species (sativa, indica, and ruderalis) and their physical characteristics, accompanied by photographs. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to the U.S. House Oversight Committee.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity